Let's talk medical research

Keith Lovell joined Antidote as CFO in September 2015, bringing more than 25 years of financial and commercial experience at companies ranging from major blue chip organizations to startups. Prior to Antidote, he was employee number 30 at Shazam, and helped build it up to a billion dollar valuation. 

The Scrip Awards are where the industry’s best and brightest are recognized for excellence across the drug development spectrum. That’s why we’re absolutely honored to announce that Antidote has been named a Scrip Awards finalist in the category of “Best Technological Development in Clinical Trials.” We’ve been a finalist in this category before, and are thrilled that the evolution of our ...

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the second in that series. 

It’s been one year since Laurent Schockmel took the helm at Antidote. We sat down with Laurent to talk about his journey from scientist to CEO and hear his reflections on his first year at Antidote. Here’s what he had to say:

Today, nearly 60 million patients are needed for currently recruiting clinical trials. And in fact, 80% of trials will be delayed or closed due to difficulty finding patients to take part. 

As medications become more targeted and sophisticated, the growing complexity of clinical trial protocols is making it more difficult than ever to find the perfect patients for your trials. That’s why a thoughtful and strategic patient recruitment strategy is key.  

While approximately 15 to 20 percent of people 65+ have Mild Cognitive Impairment (MCI), it can be difficult to identify, and difficult to determine if it is related to Alzheimer’s disease. MCI does not always lead to dementia, but people with MCI are four times more likely to develop Alzheimer’s disease and other forms of dementia than those without it — so it’s important to treat this condition ...

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the first in that series. 

With patients waiting for new and better treatments and companies waiting for results, delays in clinical trials are far from ideal. And yet, here at Antidote, we receive calls and emails every day from researchers who are missing their trial’s deadlines because they’re having trouble finding patients to take part. 

For the 1.5 million people in the United States that live with lupus, the chronic autoimmune disease severely impacts quality of life. Pain, fatigue, hair loss, cognitive issues, physical impairments, and rashes are a constant reminder that current treatments need improvement. With such an urgent need, we were excited to execute a successful recruitment campaign for a pharmaceutical client ...